
    
      A Phase 2, Randomized, Open label, Non-Inferiority Clinical Trial to Explore the Safety and
      Efficacy of Rivaroxaban compared with vitamin K antagonism in Patients with Atrial
      Fibrillation with Bioprosthetic Mitral valves - RIVER.
    
  